DNA Link, Inc. (KOSDAQ: 127120)

Market Cap	68.58B
Revenue (ttm)	19.11B
Net Income (ttm)	-6.94B
Shares Out	22.48M
EPS (ttm)	-383.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,193
Open	3,110.00
Previous Close	3,050.00
Day's Range	3,050.00 - 3,130.00
52-Week Range	1,775.00 - 4,200.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About DNA Link

DNA Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 90
• Stock Exchange: KOSDAQ
• Ticker Symbol: 127120

Financial Performance

In 2023, DNA Link's revenue was 21.95 billion, an increase of 29.26% compared to the previous year's 16.98 billion. Losses were -5.60 billion, -28.09% less than in 2022.